HBV Therapy and the Problem of Drug Resistance

  • A. J. ThompsonEmail author
  • S. A. Locarnini
Reference work entry


The current goal of management for patients with chronic hepatitis B is to achieve sustained virological suppression. This has been shown to reduce the risk of liver disease progression, including cirrhosis, hepatic failure, and hepatocellular carcinoma. Nucleos(t)ide analogue monotherapy is commonly used as first-line therapy, and most patients will require long-term antiviral therapy. As for all direct-acting antiviral agents, the emergence of drug resistance is an important clinical concern. In this chapter, we discuss the principles of HBV antiviral resistance and clinical pathways for preventing the selection of drug-resistant variants, as well as appropriate management strategies for antiviral treatment failure.


Hepatitis B Tenofovir Entecavir Adefovir Lamivudine Telbivudine Multidrug resistance Hepatocellular cancer (HCC) 


  1. Angus P et al (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125(2):292–297CrossRefPubMedGoogle Scholar
  2. Bartholomeusz A et al (2005) Mechanistic basis for HBV resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir. Hepatology 42:594AGoogle Scholar
  3. Bartholomew MM et al (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349(9044):20–22CrossRefPubMedGoogle Scholar
  4. Berg T et al (2010) Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139(4):1207–1217CrossRefPubMedGoogle Scholar
  5. Berg T et al. (2014) Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 60(4):715–22Google Scholar
  6. Brunelle MN et al (2005) Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41(6):1391–1398CrossRefPubMedGoogle Scholar
  7. Chan HL et al (2013) Tenofovir df (tdf) compared to emtricitabine (ftc)/tdf in hbeag-positive, chronic hepatitis b (chb) virusinfected patients in the immune tolerant (it) phase. J Hepatol Vol 52 (Suppl 1): S45 (A101)Google Scholar
  8. Chang TT, Lai CL (2006) Hepatitis B virus with primary resistance to adefovir. N Engl J Med 355:322–323; author reply 323CrossRefPubMedGoogle Scholar
  9. Chang TT et al (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52(3):886–893CrossRefPubMedGoogle Scholar
  10. Chen CJ et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65–73CrossRefPubMedGoogle Scholar
  11. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350(10):1023–1035CrossRefPubMedGoogle Scholar
  12. Clements CJ et al (2010) Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ 88(1):66–73CrossRefPubMedGoogle Scholar
  13. Colonno RJ et al (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6):1656–1665CrossRefPubMedGoogle Scholar
  14. Delaney WE et al (2003) The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 77(21):11833–11841CrossRefPubMedPubMedCentralGoogle Scholar
  15. Domingo E (2003) Quasispecies and the development of new antiviral strategies. Prog Drug Res 60:133–158PubMedGoogle Scholar
  16. European Association for the Study of the Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57(1):167–185CrossRefGoogle Scholar
  17. Fung SK et al (2005) Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43(6):937–943CrossRefPubMedGoogle Scholar
  18. Fung SK et al (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44(2):283–290CrossRefPubMedGoogle Scholar
  19. Gish R et al (2012) Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 12(4):341–353CrossRefPubMedGoogle Scholar
  20. Hadziyannis SJ et al (2006) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131(6):1743–1751CrossRefPubMedGoogle Scholar
  21. Harrison TJ (2006) Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis 26(2):87–96CrossRefPubMedGoogle Scholar
  22. Iloeje UH et al (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3):678–686CrossRefPubMedGoogle Scholar
  23. Kamili S et al (2009) Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 49(5):1483–1491CrossRefPubMedGoogle Scholar
  24. Keeffe EB et al (2007) Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5(8):890–897CrossRefPubMedGoogle Scholar
  25. Lai MW, Yeh CT (2008) The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. Antivir Ther 13(7):875–879PubMedGoogle Scholar
  26. Lai CL et al (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36(6):687–696CrossRefPubMedGoogle Scholar
  27. Lai CL et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25):2576–2588CrossRefPubMedGoogle Scholar
  28. Lai MW et al (2009) Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 14(2):249–261PubMedGoogle Scholar
  29. Lavocat F et al (2013) Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy. J Hepatol 59(4):684–695CrossRefPubMedGoogle Scholar
  30. Lee YS et al (2006) Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43(6):1385–1391CrossRefPubMedGoogle Scholar
  31. Liaw YF et al (2004a) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521–1531CrossRefPubMedGoogle Scholar
  32. Liaw YF, Chien RN, Yeh CT (2004b) No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9(2):257–262PubMedGoogle Scholar
  33. Liaw Y-F et al (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6:531–561CrossRefPubMedGoogle Scholar
  34. Liu Y et al (2010) Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther 15(8):1185–1190CrossRefPubMedGoogle Scholar
  35. Locarnini SA (1998) Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 27(1):294–297CrossRefPubMedGoogle Scholar
  36. Locarnini S, Qi X, Arterturn S (2005) Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil therapy for patients with chronic hepatitis B. J Hepatol 42(Suppl 1):754AGoogle Scholar
  37. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50(3):661–662CrossRefPubMedGoogle Scholar
  38. Lok AS et al (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6):1714–1722CrossRefPubMedGoogle Scholar
  39. Lok AS et al (2007) Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46(1):254–265CrossRefPubMedGoogle Scholar
  40. Lok AS et al (2012) Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 143(3):619–628.e1CrossRefPubMedGoogle Scholar
  41. Lozano R et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095–2128CrossRefPubMedGoogle Scholar
  42. Nafa S et al (2000) Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32(5):1078–1088CrossRefPubMedGoogle Scholar
  43. Ogata N et al (1999) Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59(3):270–276CrossRefPubMedGoogle Scholar
  44. Ogura Y et al (1999) Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 180(5):1444–1451CrossRefPubMedGoogle Scholar
  45. Patterson SJ et al (2011) Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60(2):247–254CrossRefPubMedGoogle Scholar
  46. Pol S, Sogni P (2010) Treatment of chronic hepatitis B: adherence and safety. Gastroenterol Clin Biol 34(Suppl 2):S142–S148CrossRefPubMedGoogle Scholar
  47. Schluter V et al (1994) Integrated hepatitis B virus X and 3′ truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 9(11):3335–3344PubMedGoogle Scholar
  48. Shaw T, Locarnini S (2004) Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2(6):853–871CrossRefPubMedGoogle Scholar
  49. Shields PL et al (1999) Selection of hepatitis B surface “escape” mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut 45(2):306–309CrossRefPubMedPubMedCentralGoogle Scholar
  50. Sloan RD et al (2008) Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant. Antivir Ther 13(3):439–447PubMedGoogle Scholar
  51. Snow-Lampart A et al (2011) No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53(3):763–773CrossRefPubMedGoogle Scholar
  52. Tenney DJ et al (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48(9):3498–3507CrossRefPubMedPubMedCentralGoogle Scholar
  53. Tenney DJ et al (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49(5):1503–1514CrossRefPubMedGoogle Scholar
  54. Thibault V et al (2002) Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16(1):131–133CrossRefPubMedGoogle Scholar
  55. Tipples GA et al (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24(3):714–717PubMedGoogle Scholar
  56. Torresi J et al (2002a) Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293(2):305–313CrossRefPubMedGoogle Scholar
  57. Torresi J et al (2002b) Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299(1):88–99CrossRefPubMedGoogle Scholar
  58. van Bommel F et al (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51(1):73–80CrossRefPubMedGoogle Scholar
  59. Villeneuve JP et al (2003) Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39(6):1085–1089CrossRefPubMedGoogle Scholar
  60. Villet S et al (2006) Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131(4):1253–1261CrossRefPubMedGoogle Scholar
  61. Villet S et al (2007) Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46(3):531–538CrossRefPubMedGoogle Scholar
  62. Villet S et al (2008) Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48(5):747–755CrossRefPubMedGoogle Scholar
  63. Warner N, Locarnini S (2008) The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48(1):88–98CrossRefPubMedGoogle Scholar
  64. Yeon JE et al (2006) Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 55(10):1488–1495CrossRefPubMedPubMedCentralGoogle Scholar
  65. Yim HJ et al (2006) Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44(3):703–712CrossRefPubMedGoogle Scholar
  66. Yuen MF et al (2001) Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34(4 Pt 1):785–791CrossRefPubMedGoogle Scholar
  67. Yuen LK et al (2007) SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 75(1):64–74CrossRefPubMedGoogle Scholar
  68. Zhou T et al (1999) Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 43(8):1947–1954PubMedPubMedCentralGoogle Scholar
  69. Zollner B et al (2001) Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 65(4):659–663CrossRefPubMedGoogle Scholar
  70. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5):1593–1608.e1-2CrossRefPubMedGoogle Scholar
  71. Zoulim F, Locarnini S (2012) Management of treatment failure in chronic hepatitis B. J Hepatol 56(Suppl 1):S112–S122CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of GastroenterologySt Vincent’s Hospital Melbourne and The University of MelbourneFitzroyAustralia
  2. 2.Victorian Infectious Diseases Reference LaboratoryNorth MelbourneAustralia

Personalised recommendations